Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation

Jennifer L. Taylor‐Cousar, Raksha Jain · Journal of Cystic Fibrosis · 2021 · 111 citations

Medicine, Maternal Health, Obstetrics +14

Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy

Christopher N. Fortner, Julie M. Seguin, Denise M. Kay · Journal of Cystic Fibrosis · 2021 · 110 citations

Medicine, Child Health, Pediatrics +14

Attitudes and Decision Making Related to Pregnancy Among Young Women with Cystic Fibrosis

Traci M. Kazmerski, Theresa Gmelin, Breonna Slocum et al. · Maternal and Child Health Journal · 2016 · 87 citations

Medicine, Gynecology, Obstetrics +16